^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TPM4 (Tropomyosin 4)

    i
    Other names: Tropomyosin 4, Tropomyosin Alpha-4 Chain, TM30p1, Epididymis Secretory Protein Li 108, Tropomyosin-4, HEL-S-108, TPM4
    8d
    TPM4::ALK Rearranged Cutaneous Epithelioid Vascular Tumor: A Case Report. (PubMed, J Cutan Pathol)
    RNA sequencing revealed an in-frame fusion between TPM4 Exon 8 and ALK Exon 20. Conservative excision was performed and recurrence has not been observed at one-year follow-up.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TPM3 (Tropomyosin 3) • CD34 (CD34 molecule) • TPM4 (Tropomyosin 4)
    |
    ALK rearrangement • ALK fusion
    8d
    Noninvasive, Rapid, and Precise Identification of Esophageal Cancer via Salivary Extracellular Vesicle-Based Diagnosis. (PubMed, ACS Nano)
    Our streamlined EV isolation and identification workflow facilitates noninvasive biomarker discovery for early-stage esophageal cancer detection. This study extends the EXODUS platform to salivary EVs for EC detection, documents matrix-specific workflow optimizations, and identifies saliva-derived biomarker signatures integrated into a multimarker diagnostic model.
    Journal
    |
    LMNA (Lamin A/C) • CALR (Calreticulin) • TPM4 (Tropomyosin 4) • AGRN (Agrin)
    28d
    The Extended Spectrum of Morphologic and Molecular Findings in ALK Fusion Spitz Neoplasms: A Study of 144 Cases. (PubMed, Am J Surg Pathol)
    A meta-analysis of the literature suggests that adverse events tend to be associated with c-MYC amplification, CDKN2A homozygous deletion, and higher mitotic count (5.5 mitoses/mm2 in metastatic cases vs. 2.2 mitoses/mm2 in nonmetastatic cases). Our study expands the morphologic spectrum and the associated genomic correlates of ALK-rearranged Spitz neoplasms and identifies parameters associated with malignant behavior.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • EML4 (EMAP Like 4) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KIF5B (Kinesin Family Member 5B) • TERT (Telomerase Reverse Transcriptase) • EHBP1 (EH Domain Binding Protein 1) • TPM4 (Tropomyosin 4) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2)
    |
    ALK rearrangement • ALK fusion • CDKN2A deletion
    3ms
    An Unusual High-Grade Sarcoma of the Kidney with TPM4::NTRK1 Fusion, CDKN2A/B Deletion, SDHD and NOTCH3 Variants: The First Case Report in Pediatric Population. (PubMed, Fetal Pediatr Pathol)
    Based on these molecular findings, the diagnosis was confirmed as an NTRK-rearranged high-grade sarcoma with an unusual histomorphological phenotype. This case highlights novel molecular characteristics of NTRK-rearranged high-grade sarcoma and underscores the critical role of comprehensive molecular profiling in diagnosing challenging cases.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NOTCH3 (Notch Receptor 3) • NTRK (Neurotrophic receptor tyrosine kinase) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TPM4 (Tropomyosin 4)
    |
    CDKN2A deletion • NTRK fusion
    4ms
    Integrating multi-omics and clinical features to model survival in epithelial ovarian cancer subtypes. (PubMed, Sci Rep)
    Integrating multivariate predictive modeling with biological interpretation provides a comprehensive framework for personalized risk stratification and treatment decision-making in EOC. The identified prognostic biomarkers, such as TPM4, SDHD, MUC16, and BCL6, represent potential targets for future studies and therapeutic interventions.
    Journal
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • BCL6 (B-cell CLL/lymphoma 6) • WT1 (WT1 Transcription Factor) • MUC16 (Mucin 16, Cell Surface Associated) • FAT3 (FAT Atypical Cadherin 3) • ZFHX3 (Zinc Finger Homeobox 3) • FAT4 (FAT Atypical Cadherin 4) • CSMD3 (CUB And Sushi Multiple Domains 3) • HOXA11 (Homeobox A11) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TPM4 (Tropomyosin 4)
    |
    TP53 mutation • PIK3CA mutation • PTEN mutation • ARID1A mutation
    5ms
    Biomimetic core-shell breast cancer models using alginate, gelatin, and collagen I: simulating the tumor matrix for drug evaluation. (PubMed, Int J Biol Macromol)
    Breast cancer cells proliferated in the core of all prototypes designed, forming spheroids and cell aggregates with a high resistance to doxorubicin. The addition of Collagen I to the developed model enabled the upregulation of malignancy markers (Col1A1, Ki67, FOXC2, SNAI1, NFKB1, WWTR1), invasion markers (WASL, ACTA1, MYO1E, TPM4, PODXL, ITGA2, ITGA5, MENA, EGFR, CDC42), and drug resistance markers (ABCG2, CYP1A1, BAX, HSP90AA1) occurring in vivo. The developed 3D in vitro model can clarify the contribution of the extracellular matrix to the tumor outcome and drug efficacy by replicating some key characteristics of breast tumors, establishing a novel tool for chemotherapeutic agents and drug screening.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • BAX (BCL2-associated X protein) • COL1A1 (Collagen Type I Alpha 1 Chain) • WWTR1 (WW Domain Containing Transcription Regulator 1) • CDC42 (Cell Division Cycle 42) • PODXL (Podocalyxin) • SNAI1 (Snail Family Transcriptional Repressor 1) • TPM4 (Tropomyosin 4) • ACTA1 (Actin Alpha 1, Skeletal Muscle) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • ITGA2 (Integrin Subunit Alpha 2) • ITGA5 (Integrin Subunit Alpha 5) • FOXC2 (Forkhead Box C2)
    |
    doxorubicin hydrochloride
    6ms
    Isoform Specificity of a Compound Targeting Actin Filaments Containing Tropomyosin Tpm1.8/1.9. (PubMed, Cytoskeleton (Hoboken))
    Tpm1.8/1.9 organisation becomes dispersed between 12- and 18-hour exposure to 189-3, and the organisation of Tpm1.8/1.9 returns within 4 h of drug washout. We conclude that the amino acid sequence differences located at 7 positions in the first 19 residues of these isoforms provide sufficient specificity to generate compounds that target Tpm1.8/1.9 alone.
    Journal
    |
    TPM4 (Tropomyosin 4)
    7ms
    The role of glycolytic condensates in the cellular stress response during cancer progression. (PubMed, Adv Biol Regul)
    We discuss the role of scaffold molecules, such as TPM4, F-actin, and RNA, in mediating condensate assembly and stabilization. A deeper understanding of the regulation and function of glycolytic condensates could reveal new vulnerabilities in tumor metabolism and generate strategies to hinder cancer cell adaptation to stress.
    Review • Journal
    |
    TPM4 (Tropomyosin 4)
    8ms
    Hypoxia upregulate TPM4 expression to strengthen epithelial-mesenchymal transition that promotes lymph node metastasis of papillary thyroid cancer. (PubMed, J Cancer)
    Functional assays demonstrated that TPM4 enhanced cellular invasion and migration capabilities. Our findings illuminate a novel mechanism whereby the hypoxic tumor microenvironment promotes lymph node metastasis in PTC through TPM4-mediated activation of EMT signaling, providing new insights into LNM of PTC.
    Journal
    |
    TPM4 (Tropomyosin 4)
    11ms
    Case Report: Clinical response of ensartinib for inflammatory myofibroblastic tumor of the urinary bladder with multiple metastases and TPM4-ALK fusion. (PubMed, Front Oncol)
    Ensartinib may provide a new therapeutic direction with promising efficacy and an acceptable safety profile for IMTUB with ALK fusion. Further clinical investigation is needed to identify its efficacy and safety.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TPM4 (Tropomyosin 4)
    |
    ALK fusion
    |
    Ensacove (ensartinib)
    11ms
    Identification of a Biomarker Panel in Extracellular Vesicles Derived From Non-Small Cell Lung Cancer (NSCLC) Through Proteomic Analysis and Machine Learning. (PubMed, J Extracell Vesicles)
    Western blotting results confirm upregulation trends for MVP, GYS1, SERPINA3, HECTD3, SERPING1 and APOD, and TPM4 is downregulated in EVs of NSCLC patients compared with healthy individuals. These findings highlight the potential of this biomarker panel for the clinical diagnosis of NSCLC.
    Journal
    |
    PVR (PVR Cell Adhesion Molecule) • MVP (Major Vault Protein) • TPM4 (Tropomyosin 4) • SERPINA3 (Serpin Family A Member 3)